Blog
RSS FeedPosted by Michael Wonder on 04 Oct 2020
Ruzurgi now available to Canadian Lambert-Eaton myasthenic syndrome patients
25 September 2020 - Médunik Canada is extremely pleased to announce that its new orphan disease product Ruzurgi (amifampridine) is now ...
Posted by Michael Wonder on 02 Oct 2020
Patients, users, caregivers, and citizens' involvement in local health technology assessment unit in Quebec: a survey
29 September 2020 - The aim of the survey was to provide an overview of local health technology assessment unit practices ...
Posted by Michael Wonder on 01 Oct 2020
New procedures for CADTH drug reimbursement reviews
30 September 2020 - CADTH initiated stakeholder consultations in June 2020 on proposals to align the procedure for its drug ...
Posted by Michael Wonder on 24 Sep 2020
Bausch Health announces Vyzulta (latanoprostene bunod 0.024% ophthalmic solution) is now approved in seven countries
24 September 2020 - Recent access wins also make Vyzulta available to more Americans and Canadians. ...
Posted by Michael Wonder on 03 Sep 2020
Multiple factors will influence pricing for COVID-19 vaccine in Canada, says health economist
3 September 2020 - Conventional drug costing models are unlikely to apply when it comes to putting a price tag on ...
Posted by Michael Wonder on 01 Sep 2020
CADTH publishes final outcome for new medicine for patients with acquired thrombotic thrombocytopenic purpura
1 September 2020 - The CADTH Canadian Drug Expert Committee has recommended that caplacizumab not be reimbursed for the treatment of ...
Posted by Michael Wonder on 24 Aug 2020
CADTH publishes final recommendation on new indication for Soliris
24 August 2020 - The new indication is for the treatment of patients with neuromyelitis optica spectrum disorder. ...
Posted by Michael Wonder on 19 Aug 2020
Launch of two biosimilars
19 August 2020 - Sandoz Canada announces an agreement with the pCPA and the launches of Ziextenzo and Riximyo. ...
Posted by Michael Wonder on 16 Aug 2020
Direct or indirect comparison: reliance on innovative drug data key to engaging data protection
15 August 2020 - The Federal Court recently issued its decision in Natco v Canada (Minister of Health), 2020 FC 788, ...
Posted by Michael Wonder on 12 Aug 2020
Rare disease drugs strategy, standard coverage in CLHIA’s 2020 budget wish list
12 August 2020 - The Canadian Life and Health Insurance Association is recommending the federal government develop a strategy for ...
Posted by Michael Wonder on 10 Aug 2020
Can multi-criteria decision analysis be implemented into real world drug decision-making processes? A Canadian provincial experience
7 August 2020 - This paper describes the implementation of multi-criteria decision analysis into a Canadian public drug reimbursement decision-making process, ...
Posted by Michael Wonder on 10 Aug 2020
Return some excess drug revenues to employers, CLHIA says in submission to PMPRB
10 August 2020 - In its submission to the Patented Medicine Prices Review Board’s draft guidelines, the Canadian Life and ...
Posted by Michael Wonder on 10 Aug 2020
B.C. family nearing finish in race to raise $2.8 million to treat baby's rare disease
8 August 2020 - Parents hope funds will pay for expensive therapy not approved in Canada for type 1 spinal muscular ...
Posted by Michael Wonder on 04 Aug 2020
Innovative Medicines Canada responds to the revised draft PMPRB Guidelines consultation
4 August 2020 - The Patented Medicine Prices Review Board's revised Guidelines will result in patients losing access to innovative ...
Posted by Michael Wonder on 28 Jul 2020
CADTH publishes final recommendation for a new combination product for HIV infection
24 July 2020 - Cabenuva (cabotegravir and rilpivirine extended release injectable suspensions) is indicated as a complete regimen for the treatment ...